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In solid tumors, rapid local intravascular release of anticancer agents, e.g., doxorubicin (DOX), from thermosensitive liposomes
(TSLs) can be an option to overcome poor extravasation of drug nanocarriers. ­e driving force of DOX penetration is the drug
concentration gradient between the vascular compartment and the tumor interstitium. In this feasibility study, we used bered
confocal uorescence microscopy (FCFM) to monitor in real-time DOX penetration in the interstitium of a subcutaneous tumor
after its intravascular release from TSLs, ­ermodox®. Cell uptake kinetics of the released DOX was quantied, along with an in-depth assessment of released-DOX penetration using an evolution model. A subcutaneous rat R1 rhabdomyosarcoma xenograft
was used.­e rodent was positioned in a setup including a water bath, and FCFM identication of functional vessels in the tumor
tissue was applied based on AngioSense. ­e tumor-bearing leg was immersed in the 43°C water for preheating, and TSLs were
injected intravenously. Real-time monitoring of intratumoral (i.t.) DOX penetration could be performed, and it showed the
progressing DOX wave front via its native uorescence, labeling successively all cell nuclei. Cell uptake rates (1/k) of 3 minutes
were found (n  241 cells), and a released-DOX penetration in the range of 2500 µm2·s−1 was found in the tumor extravascular
space.­is study also showed that not all vessels, identied as functional based on AngioSense, gave rise to local DOX penetration.
1. Introduction
Local drug delivery strategies in oncology aim at increasing
delivery of anticancer drugs in the tumor, while limiting
their exposure in healthy tissues that induces toxic side
eects, e.g., cardiotoxicity of the small molecule doxorubicin
(DOX, relative molecular mass of 544Da) [1, 2]. One
strategy devised in previous studies is the systemic injection
of long-circulating nanomedicine formulations, such as
pegylated liposomes, to facilitate drug accumulation in the
tumor tissue [3, 4]. ­is can be achieved by exploiting two
pathophysiological characteristics of solid tumors that
constitute the enhanced permeability and retention eect
(EPR) [5, 6]: (1) a higher vascular permeability because of a
lack of vessel dierentiation and (2) insu¢cient functional
lymphatics. Despite this passive drug targeting, penetration
of nanoparticles into the tumor interstitium is rather limited
[7, 8] and variable according to the tumor type [3].
Moreover, nanoparticles display slow drug release in the
tumor tissue, which often results in drug accumulation
below the minimum concentration required to induce cell
death [9].
­e advent of temperature-sensitive liposomes (TSLs),
with the rst formulation described by Yatvin et al. [10],
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allowed the design of new drug delivery strategies with a local
triggering by an external source of mild hyperthermia. -ese
drug delivery systems must fulﬁll four main criteria: (1) a long
plasma half-life, (2) a stable formulation at body temperature,
(3) a phase transition temperature corresponding to a
physiologically mild and safe hyperthermia, hence the name
of low temperature-sensitive liposomes (LTSLs), and (4) a
“fast” drug release rate from the liposomes when more than
50% of their payload was released within around half a minute
when exposed to their phase transition temperature [11, 12].
Needham and coworkers were the ﬁrst to incorporate lyso-
lipids in themembrane bilayer and paved the way for an LTSL
formulation that was clinically compatible [13].
Combination of LTSLs with an external heat source
allowed local treatment, and Manzoor et al. introduced the
concept of triggered, rapid intravascular release [14]: upon
external triggering the LTSLs release the drug payload
rapidly in the tumor vasculature and build up a drug
concentration gradient between the tumor vasculature and
the tumor tissue, which constitutes the driving force of
diﬀusion that is the main source of transport for small
molecules, e.g., DOX [15]. -is drug penetration is pro-
portional to the drug concentration gradient. Using TSLs
with a fast drug release rate, one can therefore maximize
drug penetration into the tumor.
To conduct drug distribution studies at the tissue scale,
dorsal skin-fold window chambers have been used in vivo.
-ese consist of a skin ﬂap held vertically with an aluminium
saddle that is sutured to the upper and the lower parts of the
ﬂap [16–18]. An optical window gives access to the fascial
tissue and its vasculature, and tumor cells can be implanted
into this window chamber. An alternative intravital imaging
solution is ﬁbered confocal ﬂuorescence microscopy
(FCFM); this modality allows real-time ﬂuorescence imag-
ing in a minimally invasive fashion by directly placing a
ﬁber-based optical probe in contact with the tissue of interest
in its natural physiological environment. FCFM is mainly
used in clinical applications involving hollow organs, like in
gastroenterology [19] and pulmonology [20], either visu-
alizing the tissue based on its autoﬂuorescence or after
injection of ﬂuorescein or indocyanine green.
In this study, we tested the feasibility to use FCFM to
monitor in vivo in real-time DOX penetration in the tumor
interstitium after intravascular release of DOX from the TSL
(-ermodox®). -e kinetic analysis from the time seriesallowed quantifying (1) the local uptake kinetics of released
DOX in each individual cell of the interstitium after release
from the TSL; (2) the kinetics of the apparent released-DOX
penetration using the transport equation; and (3) the
released-DOX deposition, the vascular washout, and the
drug diﬀusion by means of an evolution model from the
ﬂuorescence signal intensity.
2. Materials and Methods
2.1. Experimental Setup
2.1.1. Animals and Tumor Model. All procedures were
performed according to the ethical guidelines and were
approved by the animal welfare committee of Utrecht
University (DEC 2014.III.03.035, Utrecht, the Netherlands).
WAG/Rij rats were purchased from Charles River (Cologne,
Germany). -ey were maintained at room temperature with
12 h light cycle in individually ventilated isolation cages and
were fed ad libitum. -e rats were 12weeks old at the be-
ginning of the experiments, weighing 250 g. Under gaseous
anesthesia (Aerrane, Baxter, Deerﬁeld, IL), a skin incision of
a few millimeters was performed at the hind leg. Sub-
sequently, rat R1 rhabdomyosarcoma tumor pieces (1–
3mm3) were subcutaneously implanted in the hind leg using
a trocar. When the tumor volume reached 1500 µm3, ap-
proximately after 3weeks of tumor growth, the drug ad-
ministration and imaging experiments were performed.
2.1.2. Chemicals. Lysothermosensitive liposomal formula-
tion of DOX (-ermodox®-TSL) at 2mg/mL was obtainedfrom Celsion Corp (Lawrenceville, NJ, USA). -ese nano-
particles release their payload as a burst in the temperature
range of 39.5°C to 42°C, i.e., less than 5% of release at 37°C,
and more than 65% at 41°C, within about 30 sec (in vitro data
provided by Celsion Corp.). On the day of the real-time
monitoring experiment, the -ermodox® solution was ﬁl-tered using a PD10-desalting column (GE Healthcare
Europe GmbH, Eindhoven, the Netherlands) to ensure that
the DOX penetration that was monitored was fully encap-
sulated previously in the TSL. -e rodents were adminis-
tered intravenously with a -ermodox® dose of 4mg/kg.Doxorubicin hydrochloride (Sigma-Aldrich, St-Louis,
MO) (relative molecular mass: 580Da), named “free
DOX” in this study, was injected intravenously at 4mg/kg.
An intravascular ﬂuorescence label, AngioSense 680 EX,
was purchased from Perkin Elmer (Waltham, MA, USA).
AngioSense is a 70 kDa near-infrared labeled-ﬂuorescent
polymer (excitation/emission wavelengths: 670/690 nm),
which allows imaging the blood pool during the whole
imaging session.
2.1.3. Fibered Confocal Fluorescence Microscopy.
Fluorescence images were acquired in real-time (8.5Hz) for
20minutes using a dual-band FCFM system (Cellvizio®dual-band, Mauna Kea Technologies, Paris, France). Native
ﬂuorescence of DOX was collected with the 488 nm exci-
tation channel, henceforth referred to as “green channel,”
and blood vessels via AngioSense with the 660 nm channel,
referred to as “red channel”. -eir spectral sensitivity is
500–630 nm and 680–800 nm, respectively. A 1.5 mm di-
ameter FCFM microprobe (PF-2210, Mauna Kea Technol-
ogies) was used (Figure 1(c)), with the following imaging
speciﬁcations: lateral resolution 3.3 μm, ﬁeld of view (FOV)
602 μm× 602 μm, axial resolution 15 μm, working distance
0 μm.-e tissue was excited at 4mW of laser power for both
channels.
2.1.4. Animal Positioning. A water bath (Memmert,
Schwabach, Germany) was used to ensure a mild and ho-
mogeneous tumor heating (Figure 1(b)). -e water
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temperature was monitored using ber optic temperature
sensors (Luxtron, Lumasense Technologies GmbH, Frank-
furt, Germany). A custom-made platform was designed to
position the animal above the water surface and to immerse
only the tumor bearing leg (Figure 1(b)).
­e animal was thermally isolated from the water bath
using a piece of aluminium foil (Figure 1(b)). ­e rectal
temperature and the water temperature (set to 43°C) in the
vicinity of the tumor were monitored during the session.
During the whole experiment, the rectal temperature was
lower than the phase transition temperature of the TSL
(Figure S1). ­e hind leg bearing the tumor was positioned
in the water bath for 10minutes, which was su¢cient to get
the tumor tissue at 43°C (data not shown).
Handling of the FCFMmicroprobe was facilitated by using
a modular hose, holding it in xed position in contact with the
tumor tissue, such that a dynamic microscopy time series of a
xed tumor location could be obtained (Figure 1(b)).
2.1.5. Timeline of the Imaging Session. ­e rats were
anaesthetized with an i.p. injection of 75mg/kg of ketamine
(Narketan, Vetoquinol, ’s-Hertogenbosch, the Netherlands)
and 0.25mg/kg of dexmedetomidine (Dexdormitor, Orion
Pharma, Mechelen, Belgium). ­en, the jugular vein was
catheterized, a 1 cm skin ap was created at the tumor level
(Figure 1(a)), and the rats were then injected intravenously
with 192 nmol·kg−1 of AngioSense (Figure 1(d)).
Subsequently, the rats were positioned on the platform of
the water bath, laying on the ank, with the tumor bearing leg
immersed in the 43°C water. Temperature probes were then
placed to monitor the temperature of the water bath and the
body temperature of the animal. ­e tip of the FCFM probe
was placed manually to make contact with the tumor tissue in
the water, and the tumor was explored until tortuous tumor
vessels were found. ­en, stability of the FOV was veried by
waiting one minute and by checking any motion of the tumor
microvasculature in the image. ­e syringe containing
­ermodox® was only then placed in the catheter, to avoidpremature heating of the liposomes. At this point, the 20-
minute real-time monitoring was started. After collecting the
10-second baseline with tissue autouorescence, a 4mg/kg
bolus injection of TSLs, or free DOX, was administered in-
travenously in the jugular vein in around 40 s.
After completion of the dynamic sequence, exploration
of the tumor surface was performed manually with the
(a) (b)
5 mm
(c)
Anesthesia
10 s 50 s
Experimental Timeline
Jugular vein
catheterization
Skin flap for
tumor access
AngioSense injection
Rat positioning
in setup
Search for
tumor vasculature
ThermoDox® injection
(jugular vein)
Tumor preheating Dynamic monitoring
Tumor screening
with FCFM probe
Organ, blood, and
urine harvesting
(d)
Figure 1: Tumor access (a), setup (b), tip of the FCFM probe (c), and timeline of the experiment (d). After incision of the skin at the tumor
location (a), the rat was positioned on a platform placed at the water surface of the water bath, with the hind leg immersed in the water set to
43°C (b).
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FCFM probe, andmicrographs were acquired to evaluate the
presence of DOX in the tumor microenvironment by means
of its native ﬂuorescence [21, 22].
At the end of the session, the rats were sacriﬁced by an
i.p. injection of 200mg/kg of pentobarbital (Euthanimal
20%, Alfasan,Woerden, the Netherlands), and the blood, the
urine if any, and the tumor were harvested.
Two treatment groups consisted of the “free DOX” group
(n � 3) and the “TSL” group (n � 5).
3. Histopathology and Liquid Biopsy Analysis
Tumors were harvested and ﬁxed in the formol-acetic acid
solution. -en, histological samples were embedded in
paraﬃn, cut at approximately 5 μm, and prepared using
conventional hematoxylin/eosin protocol. -e tissue sec-
tions were examined by light microscopy on a Keyence
microscope (Keyence International, Belgium). Whole tumor
imaging was performed using a 4x magniﬁcation objective
(numerical aperture 0.6) and the mosaicking module with a
7-by-7 matrix. -e size of the neoplastic nodule on the slide
was measured with a ruler.-en, micrographs of each tumor
area (necrotic versus proliferative areas) were acquired at
20x magniﬁcation using a PlanFluor objective (Numerical
aperture 0.5) and at 60x using an oil-immersion PlanApo
VC objective (numerical aperture 1.4).
Micrographs of DOX ﬂuorescence in frozen-tissue
sections were acquired using a Leica TCS SP8 X confocal
ﬂuorescence microscope, with a 10x magniﬁcation objective,
a 504 nm excitation wavelength, and an emission ﬁlter of
540–680 nm.
DOX concentration in blood and urine samples was
measured using Ultra Performance Liquid Chromatography
(UPLC) with ﬂuorescence and UV detection. An ACQUITY
UPLC BEH C18 separation column was used (130 A˚ngstro¨m,
size of 1.7micron, 1.7× 50mm). -e mobile phase consisted
of an eluant with the following mixture: 75% reverse-osmosis
water, 25% acetonitrile, and 1% perchloric acid. During
separation, a column temperature of 50°C and a sample
temperature of 25°C were set, with 3 minutes of run time.-e
ﬂuorescence was measured with a 480 nm excitation/565 nm
emission and a UV detection of 234 nm.
4. Kinetic Analysis of Released-
DOX Penetration
-e real-time ﬂuorescence image data obtained was pro-
cessed oﬄine using MATLAB® 2013 (-e MathWorks,Natick, MA, USA). To increase the signal-to-noise ratio, the
sequence was averaged temporally to an 8 s frame rate.
Kinetic analysis of DOX penetration consisted of the 3
following independent but complementary sections.
4.1. Cell Uptake Kinetics of Released-DOX. Cell uptake ki-
netics was assessed using the dedicated parametric pipeline
described in Derieppe et al. [23]. Brieﬂy, this automated
pipeline includes cell detection, which was facilitated by a
nonlocal means algorithm [24], a cell tracking with the
iterative-closest-point algorithm [25], and a ﬁtting of the
resulting uptake proﬁles by means of a two-compartment
model where the ﬂuorescence signal intensity (I) is as follows
[26]:
I(t) � A 1− e−k(t−T)[ ], (1)
where A is the maximum DOX ﬂuorescence signal, T the
time of signal onset, and k the uptake rate. -e model was
considered accurate when Pearson’s correlation coeﬃcient
(r2) was greater than 0.95; the values of the uptake rate of
released DOX were reported as median with interquartile
ranges. -en, a statistical analysis of the resulting phar-
macokinetic parameters of the cell population visible in the
FOV was performed.
4.2. Analysis of the Released-DOX Penetration in the Tumor
Interstitium. Quantitative evaluation of released-DOX
penetration in the tumor interstitium was then performed
by estimating the instantaneous apparent DOX transport
(noted V
→
) using the transport model applied to all acquired
images [27]. In practice, the following equation was applied
in a homogeneous environment to calculate the in-
stantaneous released-DOX penetration between timepoints t
and t+ δt:
It + V
→
· ∇→I � 0, (2)
where I denotes the native ﬂuorescence signal monitored in
the green channel and It the partial temporal derivative of I
calculated between the timepoints t and t+ δt.-e left part of
this equation consists of a transient term (It) and an ap-
parent transport V
→
· ∇→I, which stand for any temporal and
spatial grey intensity variations, respectively. -e sum of
both terms equal 0 to ensure the signal intensity conser-
vation with motion in the ﬁeld of view. Any spatiotemporal
intensity variations occurring between timepoints t and
t+ δtmay be attributed to DOX transport in the model used.
-e estimated transport ﬁeld V
→
thus accounts for spatio-
temporal ﬂuorescence intensity variation occurring during
the dynamic imaging sequence.
-e transport model of equation (2) is intrinsically
underdetermined, thus leading to an ill-conditioned nu-
merical scheme. -e transport ﬁeld V
→
was therefore com-
puted on a pixel-by-pixel basis by applying the minimization
process as follows:
argmin
V
→
∫Ω∣∣∣∣It + V→ · ∇→I∣∣∣∣ + α(����∇→u����22 + ����∇→v����22) d r→, (3)
where Ω⊆R2 is the coordinate domain of the image, (u, v)
the components of transport vectors estimated, and r→ ∈ Ω
the spatial location. -e minimized functional consists of
both additive contributions as follows: (1) a ﬁdelity term (left
part of the integral in equation (3)) that optimizes, through
an L1 norm, the transport model of equation (2); given that
an L1 penalizer is applied, transient variations occur iden-
tically, and regardless of the grey level intensity, (2) a reg-
ularization term (equation (3), right part of the integral)
designed to introduce a suﬃcient conditioning to the
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numerical scheme. -e regularization term is given by
����∇→u����22 � u2x + u2y and ����∇→v����22 � v 2x + v 2y , ux, uy, vx with vy
being the spatial partial derivatives of u and v, respectively.
Physically, this regularization term assumes that the
transport between neighboring pixels is moderate.
-e data ﬁdelity and the regularization terms are linked by
the weighting factor α that was set to 1.0 in the scope of this
study.-is value was motivated by the fact that a high α value
increases the stability of the numerical scheme but also
hampers in turns the “spatial elasticity” of the estimated
displacement ﬁeld. In order to optimize the computation time
and to ensure the convergence of the algorithm, a multi-
resolution scheme that iterated the registration algorithm was
used from a four-fold down-sampled image step-by-step to
the full image resolution [28].-e interested reader is referred
to Corpetti et al. [29] for more information about the nu-
merical resolution of dense estimation of ﬂuid ﬂows.
In order to mitigate the local impact of the nucleus
ﬂuorescence signal on DOX penetration in the interstitium,
a spatial low-pass Butterworth ﬁlter was applied to each
individual image before the resolution of equation (3). In
order to remove cell nuclei with typical diameters up to
10 μm, according to an image pixel size of 1.0×1.0 µm2, the
cut-oﬀ frequency fc of the low-pass ﬁlter was set to
fc � f0/16, f0 being the original image sampling frequency.
-e onset of ﬂuorescence signal was deﬁned when the
maximum ﬂuorescence signal in the current image exceeded
at least 5% of the maximum signal of the sequence. Since the
transport model of equation (2) relies on the spatiotemporal
ﬂuorescence intensity, the analysis of the released-DOX
penetration in the interstitium was performed on images
acquired after this timepoint.
A principal component analysis (PCA) was applied
subsequently on the time series of the computed 2-di-
mension penetration vector ﬁelds in order to ﬁnd the spatial
orthogonal basis; the resulting principal axis served to
generate an adequate representation of the sequence of
displacement ﬁelds. An averaged motion amplitude along
each principal axis was then calculated for each individual
displacement ﬁeld and allowed calculating the temporal
proﬁle of the average motion amplitude along each principal
axis.
4.3. Modeling of Released-DOX Penetration. Ultimately, the
spatiotemporal distribution of released-DOX ﬂuorescence
signal intensity S was modeled and included a uniform
released-DOX deposition δ, a vascular washout ω pro-
portional to the current ﬂuorescence signal intensity, and a
homogeneous released-DOX apparent diﬀusion ] in the
FOV, with the following equation:
z
zt
S( r
→
, t) � δ −ω · V( r→) · S( r→, t) + ] · ΔS( r→, t), (4)
where Δ is the Laplacian operator, t is the time instant, r→ �
(x, y, z) is the voxel coordinate, and V( r→) is a probability
density function (PDF) that has a value close to 1 (0, re-
spectively) in voxels having a high (low, respectively)
probability to be in the vascular space. Here, only diﬀusion
was considered, as diﬀusion is dominant for small mole-
cules, such as doxorubicin, in the extravascular space [15].
In this model, the ﬂuorescence signal intensity S( r→, t)
was collected in the green channel. -e PDF V( r→) was
derived from the ﬂuorescence signal in the vessels collected in
the red channel at the beginning of the acquisition.-is signal
was normalized between 0 and 1 and assumed to be tem-
porally invariant (a linear relation between the ﬂuorescence
signal in the vessels and the PDF was assumed to be a good
approximation in the scope of this study). -e coeﬃcients δ,
ω, and ] were assumed to be spatially and temporally in-
variant within a temporal window covering the time period
starting from 100 seconds, which corresponds to the onset of
ﬂuorescence signal in the FOV, to 20minutes of imaging.
Equation (4) was solved using a ﬁnite diﬀerence method
integrated in an explicit Euler scheme in order to simulate
the evolution of ﬂuorescence signal intensity for speciﬁc
values of δ, ω, and ]. Using a Levenberg–Marquardt ﬁt, the
coeﬃcients δ, ω, and ] were calculated to minimize the least-
square residue between the model and the measured data
over the complete sequence. -e algorithm applied multiple
regularly sampled initial conditions for ] in order to prevent
the algorithm from falling into local minima. -e goodness
of the ﬁt, as evaluated by Pearson’s correlation coeﬃcient,
was computed in order to evaluate whether the model de-
scribed accurately the ﬂuorescence signal enhancement.
Since cell nuclei are nonmoving structures, the impact of
their ﬂuorescence signal was reduced using a spatial low-
pass Butterworth ﬁlter (order 1) in each individual image
before the numerical resolution of equation (4). Similar to
section 4.2, the cut-oﬀ frequency fc of the low-pass ﬁlter was
set to fc � f0/16.
5. Results
5.1. Histopathological Analysis. To evaluate the inﬂuence of
mild hyperthermia on tumor tissue, histopathological an-
alyses were carried out at the end of our imaging session.
Tumors were visible as rounded neoplastic nodules present
within the subcutaneous and muscle tissues and partially
surrounded by thin ﬁbrous capsules. All tumors (37°C vs
43°C) exhibited common histopathological characteristics.
-e proliferation areas weremade up of poorly diﬀerentiated
neoplastic cells within a ﬁne vascular stroma. -ese cells
were highly pleomorphic with one or more prominent
nuclei. Some multinucleated cells were also observed in all
tumors. -e transition proliferative/necrotic areas are well-
deﬁned, with a loss in cell density and a clear ﬁbrillary aspect
that is characteristic of the extracellular matrix in the ne-
crotic area (25–30% of all tumor nodules). Few multifocal
inﬁltrations of neutrophils were observed in all tumors. No
apparent tissue damage in any of the areas exposed to a 43°C
local hyperthermia (Figure S2) was observed in comparison
to the control tumors (Figure S2).
5.2. Real-Time Monitoring of Released-DOX Penetration.
In the red channel, staining of the blood pool by AngioSense
allowed ﬁnding functional, characteristically tortuous,
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tumor microvasculature (Figures 2(a), 2(c), 2(e), and 2(g)).
In the free DOX group, i.v. injection did not lead to a de-
tectable FCFM signal (n � 3), neither during the real-time
monitoring (Figure S3) nor during histopathology
(Table S1). Conversely, in the TSL group (n � 5), a ﬂuo-
rescence signal enhancement was collected (n � 2, Table S1),
but not in the other animals (n � 3). Due to image drift in
one animal, only the onset of DOX ﬂuorescence increase
could be analyzed but not the complete DOX dynamics and
distribution.
-e ﬂuorescence signal enhancement was present in the
extravascular space, as well as in the cell nuclei of the tumor
interstitium, which reﬂected intracellular uptake of released
DOX. Interestingly, the onset of DOX uptake in the cells
started from one side and progressively spread to involve
cells throughout the FOV (Figures 2(b), 2(d), 2(f), 2(h), and
2(i)). However, no DOX ﬂuorescence enhancement was
visible in vessels. In the red channel, the ﬂuorescence of
blood vessels decreased during the acquisition probably
owing to photobleaching, but it was still possible to locate
them until 12minutes of acquisition, indicating that the
position of the FOV was steady.
5.3. Cell-Uptake Kinetics of Released-DOX. Real-time
monitoring of released-DOX penetration in the tumor
interstitium shows cell nuclei that display increasing ﬂuo-
rescence signal (Figures 2(b), 2(d), 2(f), 2(h), and 2(i)), thus
indicating an increasing DOX concentration upon cell
uptake. 241 cell nuclei could be detected and were included
in the analysis. -e maximum ﬂuorescence intensity derived
from the ﬁt (124 a.u., with interquartile range of 49 a.u.)
(Figure 3(a)) did not display any spatial correlations in the
maximum-ﬂuorescence-intensity map, neither in the FOV,
nor with the position of the vessels in the FOV (Figure 3(b)).
Of all nuclei, the median of uptake rates 1/k was 2minutes
54 s (interquartile range 4minutes 40 s) (Figure 3(d));
however, remarkably faster uptakes (range 0–3minutes 20 s)
were observed in the upper-right half of the FOV
(Figure 3(e)). In this case, no clear spatial correlation with
the microvasculature could be identiﬁed (Figure 3(e), red
dotted lines in background), indicating that released-DOX
inducing the ﬂuorescence signal did not originate from the
microvessels visible in the FOV, but instead from vessels
beyond the confocal slice.
5.4. Analysis of the Interstitial Released-DOX Penetration.
-e spatiotemporal distribution of the released-DOX native
ﬂuorescence directly reﬂected released-DOX penetration
(Figures 4(a)–4(e)) and was assessed using the ﬂuid dy-
namics model described by equation (2) through the min-
imization process of equation (3). -e arrival of DOX was
visible in the upper-right corner of the FOV 3minutes after
bolus injection and pointed toward the lower-left corner of
the FOV (Figure 4(i)).
-e principal component analysis allowed determining
the main direction of released-DOX penetration, with 94%
of relative displacement along the principal axis 1
(Figure 4(k)). -e temporal proﬁle of relative displacement
along the principal axis 1 displayed a periodic pattern
(Figure 4(l)). Released-DOX penetration then equilibrated
in the FOV 4minutes after the detected ﬂuorescence onset,
according to the low-amplitude displacement vectors
(Figure 4(j)).
5.5. Modeling of Released-DOX Penetration. Released-DOX
penetration was modeled using the evolution model of
equation (4) (Figure 5).-e quality of the ﬁt, as computed by
the sample Pearson’s correlation coeﬃcient, was equal to
0.89, reﬂecting a close match of our proposed model with the
experimental data. It is to be noticed that this model only
used the background ﬂuorescence as input, with a negligible
impact of the nucleus ﬂuorescence observed in the acquired
sequence (Figures 5(a)–5(d)); this was conﬁrmed by the
maps of the residuals (Figures 5(i)–5(l)), i.e., the diﬀerence
between the experimental data and the evolution model. -e
estimated drug diﬀusion ] was approximately 2500 µm2·s−1
(see Figure 5(m)).
5.6. Observation of the Tumor Surface by FCFM. After
monitoring dynamically DOX penetration after in-
travascular release at a single location, manual exploration of
the tumor surface by the FCFM probe showed heterogeneity
of DOX distribution in the tumor (Table S1). Interestingly,
the native ﬂuorescence of DOX was predominantly located
close to the vessels imaged in the red channel (Figure S4a)
and showed a pattern similar to that found during the real-
time monitoring with high signal from the cell nuclei
(Figure S4b). However, despite the presence of tortuous
vessels (Figure S5a), a nonnegligible amount of locations in
the same tumor did not show any DOX ﬂuorescence
(Figure S5b), suggesting heterogeneity in DOX distribution
in the tumor. In these cases, after sacriﬁce of the animal, a
tumor incision allowed insertion of the FCFM probe for
screening of the tumor tissue and also showed high DOX
heterogeneity within the tumor tissue (data not shown); this
heterogeneity was conﬁrmed in DOX ﬂuorescence micro-
graphs collected from ex vivo samples (Figure S6).
6. Discussion
Evaluation of drug penetration in the tumor microenvi-
ronment is key to optimize therapeutic strategies of
hyperthermia-triggered drug delivery in solid tumors. In this
feasibility study, a setup was devised to monitor DOX
penetration in the tumor interstitium in real time after
intravascular release of DOX from TSL. Here, we used
FCFM as an alternative of commonly used dorsal skinfold
window chambers to assess drug penetration in a
mechanically unrestricted tumor microenvironment.
First, no apparent microstructural changes could be
observed in tumor tissue exposed to a 43°C mild hyper-
thermia, thus conﬁrming the noninvasive nature of the
hyperthermia procedure. Real-time imaging using FCFM
was performed at the tumor surface with a skin incision and
allowed imaging separately the vascular compartment and
released DOX after intravascular release from the TSL.
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In the TSL group, the real-time monitoring of DOX was
successful in 2 out of 5 cases in the TSL group only, but DOX
was found in every tumor when exploring the tumor rim at
the end of the imaging session. In the free DOX group, no
DOX could be detected, neither during the real-time
monitoring nor during the tumor exploration at the end
of the imaging session, suggesting that the DOX
concentration was too low to be detected in the extravascular
space. ­is could be explained by a low concentration
gradient between the tumor vasculature and the extravas-
cular space, thus limiting free DOX penetration, hence the
use of TSLs.
Released-DOX penetration kinetics could be assessed
upon imaging of cell-uptake kinetics of released DOX in the
0 min
50 μm 
(a) 0 min (b)
4 min(c) 4 min (d)
8 min(e) 8 min (f)
12 min(g) 12 min (h)
Green channelRed channel
0 40 80 120 160 2000 30 60 90 120 150
(a.u.)
50 μm 
(i)
Figure 2: Real-time monitoring of doxorubicin penetration in the tissue microenvironment after TSL intravascular release (a, c, e, g). Red
channel with AngioSenseTM (blood-pool labeling) showed that the acquisition was performed in a steady FOV and that the vessels were
functional (b, d, f, h, i). ­e green channel shows DOX uorescence signal enhancement after the bolus injection of TSL.
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Figure 3: Uptake rates 1/k derived from the two-compartment model. Boxplots of the maximum DOX uorescence intensity (a) and the
uptake rate 1/k (d) and their corresponding spatial distributions, respectively (b, e). Characteristic examples of uorescence signal en-
hancements collected in two nuclei (dark plain curves) and the tted curves derived from the two-compartment model (dashed red curves)
(c, f ). Two distinct subpopulations of uptake rates in the FOV (e) are signicantly dierent (g).
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tumor interstitium and DOX diusion coe¢cient, both in
the same dataset. Here, 241 cell nuclei could be detected
using the image processing pipeline developed previously
[23], thus allowing a statistical analysis. Uptake time con-
stants of 3minutes were found after injection of 4 mg/kg
DOX encapsulated in TSLs. Interestingly, no apparent link
could be made between the location of the microvasculature
and the direction of the propagation front when observing
cell uptake of DOX in the FOV. ­e uptake rates around
3minutes show faster uptakes than those found in previous
studies where uptake rates 1/k around 10minutes were
found with free DOX [30, 31]. ­is would conrm the
usefulness of TSLs, where a TSL intravascular release in-
duces higher DOX levels in the extravascular space and thus
higher DOX concentration gradients as a driving force for
the faster cell uptake.
Using the transport model of equation (2) together with
a principal component analysis, the released-DOX pene-
tration in the presented results was shown to occur mainly
along one axis oriented from the top-right to the bottom-left
corner of the FOV (Figure 4(k)). Relative DOX displacement
was found to equilibrate 7minutes after the detected DOX
arrival in the FOV. ­is nding would mean that the
concentration gradient, which is the driving force for DOX
penetration into the tumor interstitium, was not present
anymore between the vascular compartment and the
interstitium after 7minutes. ­e estimated relative dis-
placements here indicate that like in the cell uptake kinetics
of released-DOX computed above, no spatial correlation
between the displacement eld and the location of the
microvasculature was found. In the scope of this study, it is
important to underline that an apparent displacement is
calculated here, without taking the uid rheology into ac-
count. ­is will be worth considering in future studies.
It is important to underline that any spatiotemporal
intensity variations occurring between timepoints t and
t+ δt in equation (2) may be attributed in our model to
“displacement”. ­is assumption brings a limitation with
regards to released-DOX penetration in the interstitium,
which is likely to be biased by the uorescence signal in the
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Figure 4: Assessment of released-DOX penetration derived from the implemented uid dynamics model. (a–e) Fluorescence images
measured at 3min 10 s (a), 3min 40 s (b), 4min 10 s (c), 5min 20 s (d), and 13min 10 s (e). (f–j) Corresponding released-DOX penetration
shown by the displacement eld. For an easier visualization, only displacement vectors associated to voxels with su¢cient uorescence
signal (i.e., greater than 5% of the maximum uorescence signal intensity) are displayed. ­e principal component analysis allowed
determining the main direction of released-DOX penetration, with 94% of relative displacement along the eigenvector 1 (k). ­e temporal
prole of relative displacements along the eigenvector 1 equilibrated 7minutes after the uorescence onset (l).
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cell nuclei, as these are nonmoving image structures. Our
simulations were thus conducted on spatially ﬁltered ﬂuo-
rescence images in order to circumvent this issue. -erefore,
it is to be noted that the apparent DOX velocity estimates
logically increased when a reduced cut-oﬀ frequency fc was
applied in the low-pass spatial-image ﬁltering process be-
cause, in this case, nuclei weighted less in ﬁltered images.
Using fc � f0/16 and fc � f0/8, DOX velocity estimates
displayed less than 10% of variations, thus conﬁrming that
the local impact of the ﬂuorescence signal in the cell nuclei
was properly discarded.
-e diﬀusion coeﬃcient reﬂects the magnitude of driving
force generated by the concentration gradient built up be-
tween the vascular compartment and the tumor interstitium.
-e model of released-DOX penetration yielded a diﬀusion
estimate around 2500 µm2·s−1. In the present study, another
source of uncertainty arose from the linear intensity of the
vessel likelihood that was assumed to be located along the red
ﬂuorescence signal intensity (equation (4)). Consequently, a
small but nonnegligible drug evacuation is also assumed in the
interstitium, where positive nonzero values are found in the
images in the red channel. It is important to report that, for
instance, a greater diﬀusion coeﬃcient would logically be
found if no evacuation in the interstitium is assumed in our
model. Nonetheless, this diﬀusion estimate is greater than the
40 µm2·s−1 reported in previous studies using free DOX
[9, 30], or 150 µm2·s−1 found by Swabb et al., who established
the correlation between the tissue diﬀusion coeﬃcient at 37°C
and the solute molecular weight, i.e., 544Da for DOX [32].
-is one-order-of-magnitude discrepancy may be in line with
the use of TSLs because the payload released locally yields
higher DOX concentration in the vasculature, thus increasing
DOX concentration gradient between the vasculature and the
extravascular space, and in turn a higher diﬀusivity.
Another source of bias in the evaluation of the diﬀusion
coeﬃcients may here arise from the 2D observation of a 3D
diﬀusion process; this 2D observation is due to the design of
the FCFM. Hence, only a 2D implementation of equation (4)
could be applied, that neglects out-of-plane drug diﬀusion.
Given that the FCFM probe used here allowed imaging from
0 to 15 μm of depth, this bias could only come from out-of-
plane events occurring deeper than the 15 μm of confocal
slice.
After monitoring dynamically DOX penetration at a
single location, the manual exploration of the tumor surface
and its depth by the FCFM probe showed a clear spatial
heterogeneity in DOX native ﬂuorescence, despite the
presence of tortuous vessels and the homogeneous heating
ensured by the water bath.
Despite the detection of functional vessels with Angio-
Sense, no real-time DOX penetration could be observed by
FCFM in 3 out of the 5 animals in the TSL group whereas
histopathology showed high DOX concentration in the tumor
area in all animals (n � 5, Table S1). In addition, as clearly
shown in Figure 2, DOX penetration does not arise from all
functional vessels. Vessel functionality is identiﬁed in this
study as showing AngioSense ﬂuorescence. It should be noted
that AngioSense has been injected well before the TSL in-
jection and that its blood half-time is long (around 7h, data of
supplier). Taken together, these data indicate that vessels with
AngioSense-based functionality are not all functional with
respect to DOX penetration upon TSL injection. Two possible
mechanisms could explain this: either TSL did not (yet) arrive
in the FCFM observed region or the TSL already lost their
DOX payload upstream before arrival. -e latter explanation
may be relevant because of the very fast release of DOX from
TSL upon hyperthermia (on the order of seconds) and should
be considered when combining hyperthermia and TSLs for
regional drug delivery.
Our FCFM and data processing approach could also
serve for the study of extravasation of drug nanocarriers,
e.g., its enhancement by hyperthermia [33], provided that
the nanocarriers can be suﬃciently ﬂuorescently labeled. In
this study, however, we followed the tumor preheating
protocol in order to maximize drug uptake in the tumor,
which leads to immediate intravascular release from the
liposomes [34]. It is noteworthy that this approach may lead
to a better understanding of the relation between drug
penetration and tumor physiology characteristics, such as
the interstitial ﬂuid pressure [35] and the solid stress de-
scribed recently [36]. Last, the image processing framework
conducted in this study can be used in a broad range of
experiments where imaging modalities at the tissue scale
allow collecting pharmacokinetic parameters for the eval-
uation of drug formulations and drug nanocarriers [37].
7. Conclusions
FCFM can provide real-time visualization of DOX in vivo in
a mechanically unrestricted tumor microenvironment,
allowing the study of DOX penetration at the tissue scale.
-e proposed image analysis framework provides data on
cell uptake kinetics as well as penetration kinetics of released
DOX and thus helped to characterize the driving force
constituted by the concentration gradient after intravascular
release of DOX from the TSL.
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Supplementary Materials
Table S1: summary of the results rat-by-rat. DOX concen-
trations in urine and blood correspond to the results of
single quantitative measurements. Figure S1: representative
proﬁles of rat rectal temperature recorded during real-time
monitoring. Figure S2: micrographs showing the impact of
mild hyperthermia on the tumor microstructure in the
proliferative area (b, c, i, j), the transition area (d, e, k, l), and
the necrotic area (f, g, m, n) of the rat 4. No morphological
damage was observed at 43°C (h–n) compared to 37C (a–g)
in any of the 3 areas. Figure S3: real-time monitoring of
doxorubicin penetration in the tissue microenvironment
after free DOX intravenous injection (a, c, e, g). Red channel
with AngioSenseTM (blood-pool labeling) showed that the
acquisition was performed in a steady FOV (b, d, f, h). No
DOX ﬂuorescence signal enhancement could be observed in
the green channel after free DOX intravenous injection.
Figure S4: micrographs collected after dynamic monitoring.
In the interstitium, nuclei that take up doxorubicin (b) are
predominantly located around the vessels (a). Figure S5:
micrographs acquired after dynamic monitoring. Despite
the presence of tortuous vessels characteristic of tumor
tissue (a), a nonnegligible amount of areas in the tumor
tissue did not show any doxorubicin signal (b). Figure S6:
representative ﬂuorescence micrographs (mosaicking) of a
tumor tissue exposed to TSL. DOX distribution is hetero-
geneous. Objective: 10x. (Supplementary Materials)
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